Compared with HFHC, both CAB and HECAB reduced serum insulin and HOMA-IR, attenuated hepatic steatosis, increased SOD1 and CAT, and reduced NF-κB, IL-6, TNF-α, and IL-1β, whereas GPx1 remained unchanged. Here, IL1B is linked to fatty liver disease.